Study design
This study was an open-label, randomised trial of third-dose COVID-19 vaccine (either BNT162b2 or CoronaVac) conducted in the community in Hong Kong. The study protocol was approved by the institutional review board of the University of Hong Kong (ethics approval number UW 21–492), and is available in 